Cardiovascular diseases (CVDs) are a variety of acute and chronic medical conditions associated with an inability of the cardiovascular system to sustain an adequate blood flow and supply of oxygen and nutrients to organs and tissues of the body. The CVD conditions may be manifested by the obstruction or deformation of arterial and venous pathways, distortion in the electrical conducting and pacing activity of the heart, and impaired pumping function of the heart muscle, or some combination of circulatory, cardiac rhythm, and myocardial disorders.
These diseases are treated via the following surgical and interventional procedures:
- Coronary artery bypass graft (CABG) surgery;
- Coronary angioplasty and stenting;
- Lower extremity arterial bypass surgery;
- Percutaneous transluminal angioplasty (PTA) with and without bare metal and drug-eluting stenting;
- Peripheral drug-coated balloon angioplasty;
- Peripheral atherectomy;
- Surgical and endovascular aortic aneurysm repair;
- Vena cava filter placement
- Endovenous ablation;
- Mechanical venous thrombectomy;
- Venous angioplasty and stenting;
- Carotid endarterectomy;
- Carotid artery stenting;
- Cerebral thrombectomy;
- Cerebral aneurysm and AVM surgical clipping;
- Cerebral aneurysm and AVM coiling & flow diversion;
- Left Atrial Appendage closure;
- Heart valve repair and replacement surgery;
- Transcatheter valve repair and replacement;
- Congenital heart defect repair;
- Percutaneous and surgical placement of temporary and permanent mechanical cardiac support devices;
- Pacemaker implantation;
- Implantable cardioverter defibrillator placement;
- Cardiac resynchronization therapy device placement;
- Standard SVT & VT ablation; and
- Transcatheter AFib ablation
In 2016, the cumulative worldwide volume of these procedures is projected to approach 15.05 million surgical and transcatheter interventions. This will include:
- roughly 4.73 million coronary revascularization procedures via CABG and PCI (or about 31.4% of the total),
- close to 4 million percutaneous and surgical peripheral artery revascularization procedures (or 26.5% of the total);
- about 2.12 million cardiac rhythm management procedures via implantable pulse generator placement and arrhythmia ablation (or 14.1% of the total);
- over 1.65 million CVI, DVT, and PE targeting venous interventions (representing 11.0% of the total);
- more than 992 thousand surgical and transcatheter heart defect repairs and valvular interventions (or 6.6% of the total);
- close to 931 thousand acute stroke prophylaxis and treatment procedures (contributing 6.2% of the total);
- over 374 thousand abdominal and thoracic aortic aneurysm endovascular and surgical repairs (or 2.5% of the total); and
- almost 254 thousand placements of temporary and permanent mechanical cardiac support devices in bridge to recovery, bridge to transplant, and destination therapy indications (accounting for about 1.7% of total procedure volume).
Below is illustrated the overall global growth for each of the major categories of procedures through 2022.
There is considerable variation in the growth of cardiovascular procedures globally, but most growth is coming out of Asia/Pacific. For example, within the area of venous interventions, the growth in the use of endovenous ablation for chronic venous insufficiency is markedly higher in Asia/Pacific than in other regions, though the U.S. will remain the largest volume of these procedures.
“Global Dynamics of Surgical and Interventional Cardiovascular Procedures, 2015-2022” (Report #C500), published August 2016. See description, table of contents, list of exhibits at link. Available for purchase and download from link.